Automate Your Wheel Strategy on NVAX
With Tiblio's Option Bot, you can configure your own wheel strategy including NVAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVAX
- Rev/Share 7.7924
- Book/Share -0.4697
- PB -14.1583
- Debt/Equity -3.0229
- CurrentRatio 2.0561
- ROIC 0.46
- MktCap 1077100500.0
- FreeCF/Share -1.2205
- PFCF -5.4798
- PE 2.2373
- Debt/Assets 0.1768
- DivYield 0
- ROE -1.1551
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVAX | Citigroup | -- | Sell | -- | $6 | June 17, 2025 |
| Initiation | NVAX | BTIG Research | -- | Buy | -- | $19 | Feb. 28, 2025 |
News
Novavax shares jump as FDA signals path to COVID vaccine approval
Published: April 23, 2025 by: Proactive Investors
Sentiment: Positive
Novavax, Inc. (NASDAQ:NVAX) shares surged more than 16% after the company shared a positive update on its COVID-19 vaccine, which it believes is “approvable” based on its conversations with the US Food and Drug Administration (FDA). The company said the FDA has requested additional data on the vaccine as part of a post-marketing commitment (PMC).
Read More
NVAX Stock Tanks as HHS Secretary Raises Concern Over COVID-19 Jab
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Negative
The decline in Novavax stock follows the HHS Secretary's concerns regarding the efficacy of its protein-based COVID-19 vaccine in a recent interview.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports
Published: April 02, 2025 by: Reuters
Sentiment: Negative
The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Read More
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Published: March 31, 2025 by: Fast Company
Sentiment: Negative
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Secretary Robert F. Kennedy (RFK) Jr. over his views on immunization.
Read More
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Read More
Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Novavax, Inc. (NASDAQ:NVAX ) TD Cowen 45th Annual Health Care Conference March 4, 2025 9:10 AM ET Company Participants John Jacobs - President and Chief Executive Officer Ruxandra Draghia - Executive Vice President & Head of Research & Development Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Chris LoBianco - TD Cowen Chris LoBianco Great. So I think we'll get started.
Read More
Novavax Q4 Loss Narrower Than Expected, Sales Beat Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo Nordisk for $200 million.
Read More
Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Novavax, Inc. (NASDAQ:NVAX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Officer Ruxandra Draghia-Akli - Executive Vice President, Head of Research and Development John Trizzino - President and Chief Operating Officer Jim Kelly - Executive Vice President, Chief Financial Officer and Treasurer Robert Walker - Senior Vice President and Chief Medical Officer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Securities Eric Joseph - JPMorgan Vernon Bernardino - H.C.
Read More
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohort Completed $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 million Advanced pipeline programs, based on proven and innovative technology platform Ended full year 2024 with over $1 billion in Cash and accounts receivables Provides 2025 financial guidance …
Read More
What's in Store for These 5 Biotech Stocks This Earnings Season?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Read More
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the previous trading session.
Read More
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
GAITHERSBURG, Md. , Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m.
Read More
Novavax to Report Q4 Earnings: Here's What You Can Expect
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
Read More
Novavax (NVAX) Outperforms Broader Market: What You Need to Know
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day.
Read More
About Novavax, Inc. (NVAX)
- IPO Date 1995-12-05
- Website https://www.novavax.com
- Industry Biotechnology
- CEO John Charles Jacobs
- Employees 952